



























A year ago, I wrote a perspective “Cell cycle arrest is 
not senescence“, intended to clarify a new meaning of 
cellular senescence [1]. The perspective was not 
completely understood in part due to its title. The title 
was missing the word “yet”, which is now included. As 
discussed in the article, cell cycle arrest is not yet 
senescence and senescence is not just arrest: senescence 
can be driven by growth-promoting pathways such as 
mTOR, when actual growth is impossible. (This 
mechanism connects cellular senescence, organismal 
aging and age-related diseases, predicting anti-aging 
agents [2-6]). In brief, senescence can be caused by 
growth stimulation, when the cell cycle is arrested [7, 
8]. As one hallmark, senescent cells loose proliferative 
potential (PP) - the potential to resume proliferation. 
Importantly, inhibitors of mTOR suppress hallmarks of 
senescence during cell cycle arrest so cells stay 
quiescent but not senescent [9-13]. Such quiescent cells, 
with inhibited mTOR, retain PP. Once again, cells may 
be arrested but retain PP, the ability to restart 
proliferation, when allowed. In certain conditions, p53 
causes arrest but can preserve PP by inhibiting the 
mTOR pathway [14-16]. However, this phenomenon 
should not be misunderstood to indicate that “p53 
induces proliferation or  prevents  arrest  or  keeps  cells  
 
 

























proliferating” or “arrested cells retain proliferation”; 
rather, p53 instead regulates proliferative potential. 
Although we tried to explain what p53 does exactly 
(causes arrest, while preserving PP) misunderstanding 
nonetheless ensued. One solution is not to use the term 
PP altogether, substituting for it the term RP 
(regenerative potential). In the organism, stem cells and 
wound-healing cells, while quiescent, are capable to 
regenerate tissues after cell loss. Unlike non-senescent 
cells, senescent cells cannot divide in response to cell 
loss and therefore lose the potential to regenerate 
tissues. In cell culture, quiescent cells preserve RP. If 
the cell cycle is blocked, activation of mTOR causes 
loss of RP [17]. New concepts need new terminology. 
Instead of squeezing novel meaning into the old terms, 
here we present new terms for a new meaning of the 
aging process.  And a central term is gerogenic 
conversion or geroconversion.   
 
Geroconversion 
Mitogens and growth factors activate growth-promoting 
pathways, which stimulate (a) growth in size and (b) 
cell cycle progression. When cells proliferate, an 
increase in cell mass is balanced by division. 
Withdrawal of growth factors causes quiescence: the 
quiescent cell neither grows, nor cycles, and its 
functions and metabolism are low. In contrast, cell cycle 
















converts  an  arrest  into  senescence  (geroconversion).  By  inhibiting  the  growth‐promoting  mTOR  pathway,  rapamycin
decelerates geroconversion of the arrested cells. And as a striking example, while causing arrest, p53 may decelerate or
suppress geroconversion (in some conditions). Here I discuss the meaning of geroconversion and also the terms gerogenes,
gerossuppressors,  gerosuppressants,  gerogenic  pathways,  gero‐promoters,  hyperfunction  and  feedback  resistance,
regenerative potential, hypertrophy and secondary atrophy, pro‐gerogenic and gerogenic cells. 
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senescence (Figure 1). Hallmarks of senescence include 
a large flat morphology, senescence-associated beta-
galactosidase (SA-beta-gal) staining, cellular over-
activation and hyper-function, feedback signal 
resistance and loss of RP (that is, the inability to restart 
proliferation when the cell cycle inhibitor is removed). 
For example, in one well-studied cellular model, 
inducible ectopic expression of p21 causes cycle arrest 
(day 1) and senescence (after 3 days)  [18, 19]. At first, 
the arrested cells are quiescent-like: they are not 
hypertrophic, and they are SA-beta-gal negative and 
retain RP.  Thus, they can restart proliferation when p21 
expression is switched off. After 3 days, however, the 
cells acquire a senescent morphology and, if p21 is then 
switched off, the cells cannot restart proliferation or die 
in mitosis [19]. Importantly, while inhibiting the cell 
cycle, p21 does not inhibit the mTOR pathway [8-17, 
20, 21]. mTOR and perhaps some other growth-
promoting pathways convert quiescence (day 1) into 
senescence (day 3). Inhibition of mTOR by rapamycin 


























Similarly other inhibitors of mTOR also suppress 
geroconversion [10, 11].  For example, in some cell 
lines, induction of p53 inhibits mTOR  [22-26] and 
other anabolic pathways [27-32], thus suppressing 
geroconversion in cells arrested by ectopic p21 [14].   
By itself, p53 causes cell cycle arrest but can suppress 
geroconversion [14-17, 33-35]. In cell culture, cell cycle 
arrest and geroconversion are initiated simultaneously. 
In proliferating cultured cells (especially cancer cells) 
mTOR is activated. Many agents cause cell cycle arrest 
without inhibiting mTOR (or other growth factor-
sensing pathways). Once arrested, such cells are rapidly 
converted to senescent cells. This is accelerated 
geroconversion. So it may seem that senescence is 
“caused” by cell cycle arrest. The above examples, 
however, suggest that senescence is caused by growth-
stimulation when the cell cycle is arrested.  
 
In the organism, most cells are arrested and 
geroconversion can be slow. When chronically 
stimulated (but still arrested) they can become 
senescent. This physiological geroconversion can be 
imitated in cell culture [17]. 
 
The terms gerogenic conversion and oncogenic 
transformation sound alike.This is not a coincidence for 
choosing the term geroconversion.  Gerogenic 
conversion and oncogenic transformation are two sides 
of the same process. 
 
Gerogenic oncogenes and gerogenes 
Activation of growth factor receptors, Ras and Raf 
family members and members of the MAPK and 
PI3K/Akt pathways are universal in cancer [36-38].  All 
these oncogenes activate the mTOR pathway [39-47].  
They are gerogenic oncogenes, which drive the 
geroconversion of arrested cells. Because strong 
growth-promoting (mitogenic) signals induce cell cycle 
arrest [48-54], strong mitogenic signaling causes both 
conditions of senescence: arrest and mTOR/growth 
signal (Figure 2A). To avoid senescence, cancer cells 
must disable cell cycle control (Figure 2B) by either 
loss of p16, p53 and Rb or activation of c-myc, for 
example [36-38, 48, 55, 56]. In proliferating cells, 
gerogenic oncogenes render cells malignant and pro-
gerogenic (see below).  The same gerogenic oncogenes 
or their analogs accelerate aging and shorten life span in 
diverse species from worm to mammals. Therefore, 
these genes can be termed gerogenes [57]. Thus, the 
mTOR pathway shortens life span, whereas rapamycin 
extends life span [58-75]. Not coincidentally, Mutations 
that increase the life span of C. elegans inhibit tumor 
growth [76]. Finally, metabolic self-destruction, known 
as chronological senescence in yeast [60, 61, 77] is also 
stimulated by gerogenes and is inhibited by rapamycin 
[78].   
 
Gerosuppressors 
Gerosuppressors are genes (and their products) that 
suppress geroconversion. Gerosuppressors (for 
example, PTEN, AMPK, sirtuins, TSC2, NF-1 and p53) 
antagonize the mTOR pathway (see for ref. [57]). Their 
inactivation shortens life span in model organisms. 
Figure  1.  Quiescence  versus  senescence.  Q:  quiescent
cell.  In  the  absence  of  the  growth  factors,  normal  cells
undergo cell cycle arrest. S: senescent cell. When cell cycle is
arrested,  the  growth  signal  (if  it  cannot  reactivate  cycling)
drives senescence. 
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suppressors suppress both geroconversion and cancer. 
 
Gerosuppressants  
Gerosuppressants are small molecules (such as 
rapamycin) that suppress geroconversion. Not co-
incidentally, rapamycin also extends life span in diverse 
species from yeast to mammals. They can, in theory, be 
used to treat age-related diseases by slowing down 
aging, thus extending both maximal and healthy 
lifespan.  
 
Gero promoters  
Small molecules or drugs that can accelerate or promote 
geroconversion. One potential candidate is phorbol 
esters, which can activate mTOR in some cells.  Not 
surprisingly, it is also a tumor-promoter. 
 
Gerogenic pathways 
Gerogenic signaling pathways promote geroconversion. 
Whether gerogenic pathways cause or abrogate cell 
cycle arrest is irrelevant. For example, strong 
mitogenic/growth signals can induce cell cycle arrest, 
instead of proliferation [48-54]. Simultaneously, in 
arrested cells, growth signals cause geroconversion, 
leading to senescence (Figure 2A). As another example, 
the effects of p53 on cell cycle and geroconverion can 
be dissociated [14]. 
 
Pro-gerogenic conversion 
In proliferating cells, overactivation of the mTOR 
pathway renders them pro-gerogenic. Cancer cells are 
proliferating pro-gerogenic cells. When such cells are 






















stimulation of mTOR in normal stem cells causes 
hyper-proliferation, pro-gerogenic conversion and cell 
exhaustion [79-84], contributing to aging. 
 
Gerogenic cell 
Although loss of RP is very useful marker of 
senescence in cell culture, this marker may not play a 
key role in age-related pathologies in the organism, 
because most post-mitotic cells should not be able to 
restart proliferation anyway. (Notable exceptions are 
stem, wound-healing and satellite cells).  I suggest that 
active mTOR in arrested cells is a crucial marker of 
gerogenic cells and early senescence. Gerogenic 
(senescent) and quiescent cells can be distinguished by 
the levels of phosphorylated S6 (pS6), the ribosomal 
protein that is phosphorylated in response to mTOR 
activation: high in senescent cells and low in quiescent 
cells. Levels of pS6 in senescent cells may remain 
similar to the levels of pS6 in proliferating cells. So 
senescent/gerogenic cells have many features of 
proliferating cells. Interestingly, basal (fasting) levels 
pS6 were elevated in old mice [85]. Gerogenic cells 
could be defined as arrested cell with activated mTOR. 
The most physiologically relevant features are 
hypertrophy, hyperfunction and feedback resistance. 
 
Hypertrophy 
Growth signals during cell cycle arrest lead to an 
enlarged cell morphology.   From theoretical 
perspective, hypertrophy will eventually be limited by 
activation of lysosomes/autophagy [7]. This 
phenomenon may explain the activity of SA-beta-Gal, 
which is lysosomal enzyme [86-88] and active 
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Due to over-stimulation, senescent cells are 
hyperfunctional. For example, For example, senescent 
fibroblasts secrete many cytokines, growth factors and 
proteases (the hypersecretory senescence-associated 
secretory phenotype or SASP), senescent osteoclasts 
resorb bones, smooth muscle cells contract, platelets 
aggregate, neutrophils generate ROS, neurons charge, 
endocrine cells produce hormones. Noteworthy, SASP 
as a marker of senescence [91-99] is an example of 
hyperfunction.    
  
Feedback resistance 
Overactivation of signaling pathways causes signal 
resistance due to feedback inactivation of the signaling 
pathway. As an example, mTOR/S6K overactivation 
causes insulin and GF resistance [100-104].  
  
Secondary atrophy 
Hyperfunctions are associated with hypertrophy and 
hyperplasia. Yet, at the end, cells may fail either to 
function or to survive, leading to secondary atrophy. 
When cells fail, conditions become TOR-independent 
and terminal. This conceals hyperfunction as an initial 
cause, misleadingly presenting aging as a decline. 
  
 
From gerogenic cells to organismal aging 
You might notice that an accumulation of molecular 
damage was never mentioned in this article. It was 
unneeded. Cellular aging and geroconversion is not 
caused by accumulation of random molecular damage. 
Although damage accumulates, I suggest that the 
organism does not live long enough to suffer from this 
accumulation with one special exception that 
illuminates the rule [105]. (The weakness of free radical 
damage theory was discussed in detail [106-114]). 
 
One definition of organismal aging is an increase in the 
probability of death. Gerogenic cells (due to their 
hyper-activity and signal-resistance) may slowly cause 
atherosclerosis, hypertension, insulin-resistance, 
obesity, cancer, neurodegeneration, age-related macular 
degeneration, prostate enlargement, menopause, hair 
loss, osteoporosis, osteoarthritis, benign tumors and 
skin alterations. These conditions lead to damage -- not 
molecular damage but organ and system damage. 
Examples include beta-cell failure [115], ovarian failure 
(menopause) [116], myocardial infarction, stroke, renal 
failure, broken hips, cancer metastases and so on [6, 
117].  These are acute catastrophes, which cause death. 
I suggest that by suppressing geroconversion, 
gerosuppressants will prevent diseases and extend 
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